Physician profile
Christopher E Walsh
NPI 1588694095
$303,985.11
in general payments reported to CMS, 2019-2025
17 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $23K · 2021: $25K · 2022: $27K · 2023: $42K · 2024: $90K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $124K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $11K · Food and Beverage: $3,642 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $123,861.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,944.00 |
| Travel and Lodging | $10,593.42 |
| Food and Beverage | $3,641.97 |
| Education | $238.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $94,796.77 | 2020-2025 | |
| Novo Nordisk INC | $73,077.61 | 2019-2024 | Rebinyn |
| Genentech USA, INC. | $47,443.07 | 2019-2025 | Hemlibra |
| Csl Behring | $29,178.89 | 2019-2025 | Hemgenix |
| Pfizer INC. | $22,343.30 | 2022-2025 | |
| F. Hoffmann-La Roche Ag | $15,362.70 | 2019-2020 | |
| Shire North American Group INC | $11,078.25 | 2019 | |
| Hoffmann-La Roche Limited | $3,485.29 | 2019-2020 | |
| New York Blood Center, INC. | $2,325.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,380.00 | 2022 | |
| Genentech, INC. | $1,289.85 | 2021-2025 | Hemlibra |
| Bioverativ Therapeutics INC. | $1,060.00 | 2019 | |
| Melinta Therapeutics, LLC | $480.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $300.00 | 2025 | |
| Biomarin Pharmaceutical INC. | $205.42 | 2024 | Roctavian |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma INC. | $114.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.